3. Risikofaktorer og forebygging

Andersson, G., Wennersten, C., Gaber, A., Boman, K., Nodin, B., Uhlen, M., ... Jirstrom, K. (2014). Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC urology, 14, 36.

Barrow, P. J., Ingham, S., O'Hara, C., Green, K., McIntyre, I., Lalloo, F., ... Evans, D. G. (2013). The spectrum of urological malignancy in Lynch syndrome. Familial cancer, 12(1), 57-63.

Bartkowiak, D., Humble, N., Suhr, P., Hagg, J., Mair, K., Polivka, B., ... Wiegel, T. (2012). Second cancer after radiotherapy, 1981-2007. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 105(1), 122-6.

Bernstein, I. T., & Myrhøj, T. (2013). Surveillance for urinary tract cancer in Lynch syndrome. Familial cancer, 12(2), 279-84.

Bhattacharya, A., Li, Y., Shi, Y., & Zhang, Y. (2013). Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. Carcinogenesis, 34(11), 2593-9.

Bricker, G. V., Riedl, K. M., Ralston, R. A., Tober, K. L., Oberyszyn, T. M., & Schwartz, S. J. (2014). Isothiocyanate metabolism, distribution, and interconversion in mice following consumption of thermally processed broccoli sprouts or purified sulforaphane. Molecular nutrition & food research, 58(10), 1991-2000.

Brown, T., Slack, R., & Rushton, L. (2012). Occupational cancer in Britain. Urinary tract cancers: bladder and kidney. British journal of cancer, 107(Suppl 1), S76-84.

Catsburg, C. E., Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Cortessis, V. K., Pike, M. C., & Stern, M. C. (2014). Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles bladder cancer study. International journal of cancer. Journal international du cancer, 134(1), 125-35.

Colt, J., Friesen, M., Stewart, P., Donguk, P., Johnson, A., Schwenn, M., ... Silverman, D. (2014). 0084 A Case-Control Study of Occupational Exposure to Metalworking Fluids and Bladder Cancer Risk among Men. Occupational and environmental medicine, 71(Suppl 1), A71.

Crivelli, J. J., Xylinas, E., Kluth, L. A., Rieken, M., Rink, M., & Shariat, S. F. (2014). Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. European urology, 65(4), 742-54.

Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A., & Abnet, C. C. (2011). Association between smoking and risk of bladder cancer among men and women. Jama, 306(7), 737-45.

Garcia-Closas, M., Malats, N., Silverman, D., Dosemeci, M., Kogevinas, M., Hein, D. W., ... Rothman, N. (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 366(9486), 649-59.

Grotenhuis, A. J., Vermeulen, S. H., & Kiemeney, L. A. (2010). Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future oncology (London, England), 6(9), 1433-60.

Kiemeney, L. A., Sulem, P., Besenbacher, S., Vermeulen, S. H., Sigurdsson, A., Thorleifsson, G., ... Stefansson, K. (2010). A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nature genetics, 42(5), 415-9.

Lamm, D. L., & Riggs, D. R. (2001). Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. The Journal of nutrition, 131(3s), 1067s-70s.

Lammers, R. J., Witjes, W. P., Hendricksen, K., Caris, C. T., Janzing-Pastors, M. H., & Witjes, J. A. (2011). Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. European urology, 60(4), 713-20.

Metcalfe, M. J., Petros, F. G., Rao, P., Mork, M. E., Xiao, L., Broaddus, R. R., & Matin, S. F. (2018). Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. The Journal of urology, 199(1), 60-65.

Mork, M., Hubosky, S. G., Rouprêt, M., Margulis, V., Raman, J., Lotan, Y., ... Matin, S. F. (2015). Lynch Syndrome: A Primer for Urologists and Panel Recommendations. The Journal of urology, 194(1), 21-9.

Parkin, D. M., Boyd, L., & Walker, L. C. (2011). 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. British journal of cancer, 105(Suppl 2), S77-81.

Pashos, C. L., Botteman, M. F., Laskin, B. L., & Redaelli, A. (2002). Bladder cancer: epidemiology, diagnosis, and management. Cancer practice, 10(6), 311-22.

Rink, M., Furberg, H., Zabor, E. C., Xylinas, E., Babjuk, M., Pycha, A., ... Shariat, S. F. (2013). Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. European urology, 63(4), 724-32.

Rink, M., Crivelli, J. J., Shariat, S. F., Chun, F. K., Messing, E. M., & Soloway, M. S. (2015). Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. European urology focus, 1(1), 17-27.

Rota, M., Bosetti, C., Boccia, S., Boffetta, P., & La Vecchia, C. (2014). Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to 2014. Archives of toxicology, 88(8), 1479-90.

Rothman, N., Garcia-Closas, M., Chatterjee, N., Malats, N., Wu, X., Figueroa, J. D., ... Chanock, S. J. (2010). A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature genetics, 42(11), 978-84.

Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R. J., Burger, M., ... Shariat, S. F. (2015). European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European urology, 68(5), 868-79.

Serretta, V., Altieri, V., Morgia, G., Di Lallo, A., Carrieri, G., & Allegro, R. (2013). Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. Urology, 81(2), 277-81.

Sosnowski, R., & Przewozniak, K. (2014). The role of the urologist in smoking cessation: Why is it important?. Urologic oncology, 33(1), 30-39.

Tubiana, M. (2009). Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 91(1), 4-15; discussion 1-3.

van der Post, R. S., Kiemeney, L. A., Ligtenberg, M. J., Witjes, J. A., Hulsbergen-van de Kaa, C. A., Bodmer, D., ... Hoogerbrugge, N. (2010). Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of medical genetics, 47(7), 464-70.

Vasen, H. F., Möslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., ... Wijnen, J. (2007). Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of medical genetics, 44(6), 353-62.

Wallis, C. J., Mahar, A. L., Choo, R., Herschorn, S., Kodama, R. T., Shah, P. S., ... Nam, R. K. (2016). Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ (Clinical research ed.), 352, i851.

Wennersten, C., Andersson, G., Boman, K., Nodin, B., Gaber, A., & Jirstrom, K. (2014). Incident urothelial cancer in the Malmo Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagnostic pathology, 9(1), 189.